Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes
Journal
Metabolism: Clinical and Experimental
Journal Volume
63
Journal Issue
8
Pages
1049-1055
Date Issued
2014
Author(s)
Abstract
Objective To investigate whether pioglitazone treatment of patients with type 2 diabetes mellitus was associated with an increased risk of kidney cancer. Methods The reimbursement databases of all Taiwanese patients with type 2 diabetes who received oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006, and a total of 1,093,675 patients with type 2 diabetes were followed up for kidney cancer incidence until the end of 2009. The incidences of kidney cancer among patients who had and had not received pioglitazone, as well as among subgroups of those treated with pioglitazone (sorted by time since starting pioglitazone, duration of treatment and cumulative dose) were calculated and hazard ratios (HRs) estimated by Cox regression analysis. Results Of the 1,093,675 patients, 58,172 (5.3%) had and 1,035,503 (94.7%) had not received pioglitazone, with incident kidney cancer developing in 208 (0.36%) and 3304 (0.32%) patients, respectively, and a respective incidence of 97.7 and 90.5 per 100,000 person-years. Pioglitazone and kidney cancer were not significantly associated in unadjusted (HR 1.04; 95% confidence interval (CI), 0.90-1.20), age-sex-adjusted (HR 1.09; 95% CI, 0.95-1.25), and fully adjusted (HR 1.09; 95% CI, 0.94-1.26) models. None of the dose-response parameters showed a significant trend of risk association, with all P-trends >0.10. Conclusions Pioglitazone does not affect the risk of kidney cancer. ? 2014 Elsevier Inc.
SDGs
Other Subjects
acarbose; insulin; metformin; pioglitazone; rosiglitazone; sulfonylurea derivative; adult; aged; article; cancer incidence; cancer risk; data base; disease association; dose response; female; follow up; human; kidney cancer; major clinical study; male; national health insurance; non insulin dependent diabetes mellitus; priority journal; reimbursement; Taiwan; treatment duration; Asian population; Cohort study; Epidemiology; Insurance database; Taiwan; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Middle Aged; Risk Factors; Thiazolidinediones
Publisher
W.B. Saunders
Type
journal article